Combined Efficacy of CXCL5, STC2, and CHI3L1 in the Diagnosis of Colorectal Cancer
Table 1
Results for indicated biomarkers in the diagnosis of CRC from the non-CRC controls.
Training set (n = 627, 276 CRCs vs. 351 controls)
Testing set (n = 260, 116 CRCs vs. 144 controls)
AUC (95% CI)
Sensitivity
Specificity
Accuracy
AUC (95% CI)
Sensitivity
Specificity
Accuracy
CEA
0.739 (0.703–0.773)
0.569
0.801
0.699
0.799 (0.745–0.864)
0.661
0.819
0.749
CA 199
0.706 (0.668–0.741)
0.747
0.547
0.635
0.602 (0.539–0.662)
0.357
0.819
0.614
Model_1
0.798 (0.765–0.829)
0.576
0.903
0.753
0.804 (0.750–0.851)
0.591
0.833
0.726
CXCL5
0.847 (0.817–0.874)
0.736
0.869
0.811
0.859 (0.811–0.899)
0.774
0.861
0.846
STC2
0.866 (0.837–0.892)
0.859
0.842
0.853
0.887 (0.842–0.923)
0.922
0.799
0.853
CHI3L1
0.792 (0.758–0.823)
0.661
0.809
0.744
0.783 (0.728–0.831)
0.591
0.840
0.729
Model_2
0.943 (0.922–0.960)
0.848
0.917
0.887
0.959 (0.927–0.980)
0.878
0.917
0.900
Cutoffs: CEA: 4.44 ng/ml, CA199: 37.3 U/ml, CXCL5: 317.05 pg/ml, STC2: 232.4 pg/ml, CHI3L1: 34.41 ng/ml, Model_1: 0.5194, and Model_2: 0.517. The cutoffs were given according to the maximum Youden index calculated by ROC using training data and were then applied in the following analysis to obtain the corresponding parameters (sensitivity, specificity, and accuracy).
